Prescribing trends of HMG Co-A reductase inhibitors in outdoor patients at tertiary care teaching hospital of central India: a retrospective observational study

Sudharam T. Bhagwate¹, Renuka S. Harwani¹*, Dheeraj S. Jeswani², Sagar N. Yalgundee¹, Rupesh A. Warbhe¹

¹Department of Pharmacology, Government Medical College, Akola, Maharashtra, India
²Department of Medicine, Shija Hospital and research institute, Imphal, Manipur, India

ABSTRACT

Background: To analyze the prescribing patterns of statins a hypolipidemic agents by using HMIS database in outdoor patients at tertiary care teaching hospital of central India.

Methods: In this retrospective study Using HMIS database, 1000 prescriptions were analyzed for statin use for various WHO prescription indicators using ATC code of statins, the ratio of prescribed daily dose (PDD) and defined daily dose (DDD) was calculated.

Results: Atorvastatin was the only statin which was prescribed as monotherapy (61.1%), whereas as combination with aspirin (38.9%). While analyzing the prescriptions, it was found that patients having abnormal lipid profiles (51.8%) and normal lipid profiles (48.2%) were prescribed atorvastatin. Hypertension with diabetes (37%) was the most common disease followed by hypertension (21.2%) and diabetes mellitus (21%) for which atorvastatin was prescribed. The average number of drugs per prescription were 3.8±1.65.

Conclusions: This study depicts the use of atorvastatin in various disease conditions, both as primary and secondary preventive measures. There was no polypharmacy. Such studies should be done to educate the physicians on good prescribing practices and to rationalize use of hypolipidemic drugs.

Keywords: Atorvastatin, Dyslipidemia, HMG Co-A inhibitors, Prescription Pattern

INTRODUCTION

Coronary heart disease accounts for approximately one-third of global deaths in recent years.¹ World Health Organization (WHO) has reported that approximately 60% of Indians will be affected by cardiovascular diseases by 2020.² Fundamental lifestyle changes and several medications have been recommended to control blood cholesterol. Among all medicines, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, are a major drug class given their efficacy in reducing LDL-C.³⁵ On average, administration of statins helps to lower LDL-C by 20% to 60%⁶⁰. In addition to lowering cholesterol, statins are shown to decrease risk of coronary events by 18%, myocardial infarction by 24% and heart failure by 35%.⁹ Statins are recommended by major clinical guidelines as the drug of choice for reduction of blood lipids to prevent CVD globally.³⁵

Drug utilization studies are very essential for evaluating and analyzing the drug therapy from time to time, to observe the prescribing patterns of general physicians,
with the aim of validating the use of drugs and minimizing the adverse drug reactions. Hence, this study was planned to evaluate the prescribing patterns of HMG-CoA reductase inhibitors at tertiary care hospital.

METHODS

This was a retrospective observational study conducted in pharmacology department of tertiary care hospital. After obtaining clearance from ethical committee of institute. Data of 1000 short case file containing prescription of statins during the period from January 2015 to December 2015, were reviewed and retrieved from HMIS (Hospital Management-Information System) online database of Government Medical College, Akola.

Patients of both genders and who were in age group of 30 years and above, prescribed with at least one statin, were included in the study. Patients who were below the age of 30 years and who did not receive a single statin were excluded from the study. The prescriptions given during the follow up visits were generally regarded as same prescriptions. The selected prescriptions were analyzed for different factors such as the disease patterns, the type of statin which were prescribed for those diseases, prescribed daily dose (PDD) of statins, PDD/DDD ratio of drugs.

RESULTS

In this study atorvastatin was prescribed in moderate intensity dose (10mg or 20mg), more to males (56.8%) than females (43.2%). The mean age ±SD for males and females was 64.16±9.66 and 61.84±10.07 respectively as shown in Table 1. Atorvastatin was the only statin prescribed at tertiary care hospital. Atorvastatin was given either alone in a dose of 10 mg (in 597 patients) and 20 mg (in 403 patients) or in combination with Aspirin in a dose of 10 mg (in 389 patients out of 1000), as shown in Table 2 and 3.

Table 1: Age and sex distribution of patients on atorvastatin.

| Gender | Mean age±SD | Percentage (%) |
|--------|-------------|----------------|
| Male   | 64.16±9.66  | 56.8%          |
| Female | 61.84±10.07 | 43.2%          |

Table 2: Dose distribution of atorvastatin.

| Dose of Atorvastatin | No. of patients | Percentage |
|----------------------|----------------|------------|
| 10mg                 | 597            | 59.7       |
| 20mg                 | 403            | 40.3       |
| Mean dose: 13.91mg±4.89 |               |            |

The ATC coding, DDDs (defined daily doses) of atorvastatin and atorvastatin plus aspirin and PDD/DDD ratios were determined. Both were prescribed underdosed as shown in Table 3.

The distribution of the disease pattern with lipid profile for which atorvastatin was prescribed has been shown in Figure 1. It was observed that hypertension with diabetes (37%) was most common disease followed by hypertension (21.2%) and diabetes mellitus (21%) for which atorvastatin was prescribed.

Table 3: Prescription pattern of atorvastatin and ATC/DDD classification with PDD/DDD ratio.

| Drugs prescribed | No. of patients | % | ATC Code | DDD (WHO) | PDD | PDD/DDD | Adequacy of Dose |
|------------------|----------------|---|----------|-----------|-----|---------|------------------|
| Atorvastatin Alone | 611            | 61.1 | C10AA05 | 20        | 13.91 | 0.695   | Under dosed      |
| Atorvastatin plus Aspirin | 389     | 38.9 | C10BX   | 20        | 10   | 0.5     | Under dosed      |

Figure 2 shows percentage of other drugs which were prescribed along with atorvastatin and was found that antidiabetic drugs (92.3%) were most commonly prescribed class of drug followed by antihypertensive drugs.

Table 4 shows WHO core drug prescribing indicators, there was 100% prescriptions was with generic name.

DISCUSSION

Atorvastatin was the most commonly prescribed statin at this tertiary care hospital. In other countries, atorvastatin has been one of the most commonly used statins. On observation, it was revealed that there were 56.8% males and 43.2% females who were prescribed statins, our
findings were similar to study done by Patel KP et al.\textsuperscript{15} Maximum number of patients (49.62\%) who were prescribed statin were in age group of 61-70 years. Another study showed maximum number of males were in age group of 60-70 years and females in age group of 50-60 years.\textsuperscript{16} A majority of the patients who were prescribed atorvastatin had hypertension with diabetes (37\%) followed by hypertension (21.2\%), diabetes Mellitus (21\%) and other comorbid conditions. This may be due to the fact that these prescriptions were analyzed at a tertiary care hospital, which was a referral center for a large population, the results also revealed that statin were prescribed for these disease conditions, irrespective of the lipid profile status of the patients.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Concomitant drugs prescribed with atorvastatin.}
\end{figure}

\begin{table}[h]
\centering
\begin{tabular}{|l|c|}
\hline
Parameter & Mean (±SD)/% \\
\hline
Mean (±SD) number of drugs per prescription & 3.8±1.65 \\
\hline
Percentage of drugs prescribed by generic name & 100 \\
\hline
Percentage of encounters with antibiotic prescribed & 23.8 \\
\hline
Percentage of encounters with an injection prescribed & 21.6 \\
\hline
Percentage of drugs prescribed from WHO essential drug list & 18.18 \\
\hline
\end{tabular}
\caption{WHO core drug prescribing indicators.}
\end{table}

In this study, 48.2\% patients had normal lipid profile and 51.8\% had abnormal lipid values who were prescribed atorvastatin. This may be due to the strategy for primary as well as secondary preventions of cardiovascular complications which were as per with the latest National Cholesterol Education Programme guidelines.\textsuperscript{17} Apart from atorvastatin, patients were prescribed calcium channel blocker (29.5\%), beta blockers (26.3\%), ACE inhibitors (18.9\%), antiplatelet drugs (69.4\%), oral hypoglycemic drugs (93\%), NSAIDS (37.9\%) and antibiotics (23.8\%). Use of concomitant drugs were lower in our study as compared to another study.\textsuperscript{18}

There was no polypharmacy, because there were no prescriptions which did not match the diagnoses and there were no prescriptions with more than five drugs. The ratio of PDD to DDD gives an idea about the adequacy of dosing. A ratio of less than 1 indicates underdosing, whereas a ratio of more than 1 indicates overdosing. In this study, it was found that atorvastatin and combination of atorvastatin with aspirin was prescribed as underdosed. Other studies done on underutilization of statins have been reported.\textsuperscript{19,20}

Limitation: As this was a retrospective observational study, data was collected from short case files, we could not find if patient were taking any other hypolipidemic drug along with atorvastatin due to lack of direct contact with patients or any change in prescription on follow up visits. The Prescribing indicators are less useful in speciality outpatient clinics in referral hospitals where the drug use pattern is more complex.

\section*{CONCLUSION}

To conclude, this study has shown that polypharmacy was not there and most commonly used statins for diseases like hypertension, diabetes and ischemic heart diseases was atorvastatin as hypolipidemic drug. Drug utilization studies of this type may help in improving the quality of healthcare given to patients at tertiary care hospital.

\section*{ACKNOWLEDGEMENTS}

Authors would like to thank Hon. Dean of Government Medical college for providing access to HMIS database of institute.

\section*{REFERENCES}

1. WHO. Cardiovascular diseases (CVDs). 2015. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 28 December 2017.
2. Kumar T, Kapoor A. Premature coronary artery disease in North Indians: An angiography study of 1971 patient. Indian Heart J. 2005;57:311-8.
3. Stone NJ, Robinson JG, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Part B):2889-934.
4. NICE Clinical Guideline 181. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014. London: National Clinical Guideline Centre, 2014.

5. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818.

6. Baigent C. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.

7. Cholesterol Treatment Trialists’ Collaboration, Fulcher J, O’Connell R, Voysey M. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405.

8. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-13.

9. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy clinical perspective: 20-year follow-up of west of Scotland coronary prevention study. Circulation. 2016;133(1):1073-80.

10. Introduction to Drug Utilisation Research. WHO library cataloguing-in-publication data. Available at: www.whoceo.no/filearchive/publications/drug_Utilization_research.

11. Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65(3):270-7.

12. Ferrajolo C, Arcoraci V, Sullo MG, Rafaniello C, Sportiello L, Ferrara R, et al. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?. PloS one. 2014;9(7):e102146.

13. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clinical epidemiology. 2015;7:213.

14. Geleedst-De Vooghi M, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in the Netherlands. Drugs aging. 2010;27(7):589-96.

15. Patel K, Joshi H, Khandhedia C, Shah H, Shah K, Patel V. Study of drug utilization, morbidity pattern and cost of hypolipidemic agents in a tertiary care hospital. Int J Basic Clin Pharmacol. 2013;2(4):470.

16. Sreedevi K, Venkateswara Rao J, Fareedullah M, Vijayakumar S. A study on prescription pattern of statins in cardiovascular disease. Der Pharm Lett. 2011;3(3):393-6.

17. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Association (JAMA). 2001;285:2486-97.

18. Sharma KK, Gupta R, Agrawal A, Roy S, Kasliwal A, Bana A, et al. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Vasc Health Risk Manag. 2009;5:1007-14.

19. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health. 1999;21(1):60-4.

20. Batalla A, Hevia S, Reguero JR, Cuber GI. Underutilization of lipid-lowering therapy in coronary artery disease. Arch Intern Med. 2000;160:2683-84.